FDA: Clot Risk Up for Xeljanz in RA
(MedPage Today) -- Safety signal detected for higher dose of JAK inhibitor in postmarketing trial
Source: MedPage Today Product Alert - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology